[PDF][PDF] Cetuximab: from bench to bedside
B Vincenzi, A Zoccoli, F Pantano… - Current cancer drug …, 2010 - researchgate.net
Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant,
human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the …
human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the …
The biological properties of cetuximab
Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
J Harding, B Burtness - Drugs of today (Barcelona, Spain: 1998), 2005 - europepmc.org
The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. It
is composed of extracellular domains, including a ligand-binding domain, a hydrophobic …
is composed of extracellular domains, including a ligand-binding domain, a hydrophobic …
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
H Kimura, K Sakai, T Arao, T Shimoyama… - Cancer …, 2007 - Wiley Online Library
Cetuximab (Erbitux, IMC‐C225) is a monoclonal antibody targeted to the epidermal growth
factor receptor (EGFR). To clarify the mode of antitumor action of cetuximab, we examined …
factor receptor (EGFR). To clarify the mode of antitumor action of cetuximab, we examined …
The EGFR as a target for anticancer therapy—focus on cetuximab
J Baselga - European journal of cancer, 2001 - Elsevier
The anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibody cetuximab
specifically binds to the EGFR with high affinity, blocking growth-factor binding, receptor …
specifically binds to the EGFR with high affinity, blocking growth-factor binding, receptor …
Role of an anti-epidermal growth factor receptor in treating cancer
HW Waksal - Cancer and Metastasis Reviews, 1999 - Springer
Recent technological advances, together with the discovery of the important role many
growth factors play in modulating cell proliferation and differentiation, have led to the …
growth factors play in modulating cell proliferation and differentiation, have led to the …
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor …
R Wild, K Fager, C Flefleh, D Kan, I Inigo… - Molecular cancer …, 2006 - AACR
Although Erbitux (cetuximab) has proven therapeutic benefit in the clinical setting, the
molecular determinants predicting responsiveness to this agent are still not very well …
molecular determinants predicting responsiveness to this agent are still not very well …
Current status of cetuximab for the treatment of patients with solid tumors
DA Frieze, JS McCune - Annals of Pharmacotherapy, 2006 - journals.sagepub.com
Objective: To review the pharmacology, pharmacokinetics, clinical evidence, and safety, as
well as the potential directions for use, of the epidermal growth factor receptor (EGFR) …
well as the potential directions for use, of the epidermal growth factor receptor (EGFR) …
Cetuximab.
R Goldberg, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - search.ebscohost.com
Abstract Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal
antibody that binds to the epidermal growth factor receptor, which is important in the growth …
antibody that binds to the epidermal growth factor receptor, which is important in the growth …